The Umeå High-Intensity Training Study

Aged Clinical Trial

— Umeå HIT  

Official title:

The Umeå High-Intensity Training Study: Feasibility and Effect of High-Intensity Training in Older Sedentary People

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03765385
• Other study ID #: Dnr 2018-307-31M
• Status: Completed
• Phase: N/A
• Start date: December 13, 2018
• Est. completion date: July 10, 2020

Study information

• Verified date: September 2020
• Source: Umeå University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized controlled trial will evaluate the effect of high-intensity training (HIT) in older sedentary people. Seventy older people, aged 65 and over, will be randomized to HIT or moderate-intensity continuous training (MICT). HIT sessions will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load. MICT (control group) sessions will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity. Both groups will be performed twice weekly for 12 weeks. The study will evaluate the effects on 1) Cardiovascular function, 2) Brain health, 3) Muscular function, 4) Psychological health, 5) Physical activity, 6) Metabolic health, and 7) Examine the feasibility (attendance, achieved intensity, adverse events) as well as the experiences of HIT. Most outcomes will be assessed at baseline, 3 months (directly after intervention period), and 9 months by blinded assessors.

Description:

Information about modifications of the study protocol (September 2020): Experiences of exercising and its effects were at the 9-month follow-up collected through individual interviews instead of focus group interviews (secondary outcome measures no. 31). Due to Covid-19, at the 9-month follow-up all outcome measurements besides the questionnaire (secondary outcome measures no 9, 10, 11, 12, and 14) and interviews (secondary outcome measure no 31) were terminated for 37 of the participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: July 10, 2020
• Est. primary completion date: February 5, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Not regularly physically active at moderate or high intensity over the last year.

• Independent in activities of daily living (ADL) and able to transfer from home to exercise facility.

Exclusion Criteria:

• Chronic and progressive neurological diseases.

• Movement related conditions and functions (e.g. pain) or heart and lung conditions and diseases that prohibit exercise or tests, based on screening by a physician.

• Cognitive impairment (Mini-Mental State Examination score below 27)

Related Conditions & MeSH terms

• Aged

Intervention

Other:
• High-intensity training
Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
• Moderate-intensity continuous training
Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.

Locations

Country	Name	City	State
Sweden	Umeå University	Umeå

Sponsors (1)

Lead Sponsor	Collaborator
Umeå University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline cardiovascular capacity at 3 months and at 9 months, respectively.	Maximum oxygen uptake (VO2 max)	Baseline, 3 months, 9 months
Primary	Change from baseline cognitive function at 3 months and at 9 months, respectively.	Measured using standardized tests covering: episodic memory (free recall, paired associates), executive functions (n-back, Trail Making Test (TMT) 4, flanker task), visuospatial ability (spatial relations), working memory (digit span) and processing speed (Trail Making Test (TMT) 2 and 3). The cognitive tasks are first z-transformed and then everaged to form a unit-weighted cognitive score as well as domain specific constructs.	Baseline, 3 months, 9 months
Secondary	Change from baseline brain function at 3 months.	Assessed using functional MRI (fMRI) using two paradigms. Test A will estimate functional brain response during working memory manipulation and maintenance. Test B will estimate brain response during a pattern completion/separation paradigm. Separate analyses will be performed for fMRI paradigm A and B respectively. For each paradigm changes of % signal BOLD change will be analysed.	Baseline, 3 months
Secondary	Change from baseline brain structure at 3 months.	Assessed using standard MRI-sequences including T1w, T2w, T2-FLAIR. For structural MRI data volume (mm3) and cortical thickness (mm) will be the unit of measure.	Baseline, 3 months
Secondary	Change from baseline strength in knee extensors at 3 months and at 9 months, respectively.	Maximal isometric strength in knee extensor measured as normalized joint torque in newton meters per kilogram bodyweight (Nm/kg).	Baseline, 3 months, 9 months
Secondary	Change from baseline hand grip strength at 3 months and at 9 months, respectively.	Maximal hand grip strength measured as normalized force in Newtons per kilogram bodyweight (N/kg).	Baseline, 3 months, 9 months
Secondary	Change from baseline leg extensor muscle power at 3 months and at 9 months, respectively.	Leg extensor power in the Nottingham Power Rig, measured as peak power output (watt).	Baseline, 3 months, 9 months
Secondary	Change from baseline functional performance at 3 months and at 9 months, respectively.	Chair-stand test, number of chair-stands during 30 seconds.	Baseline, 3 months, 9 months
Secondary	Change from baseline functional balance at 3 months and at 9 months, respectively.	One-leg stance: number of seconds able to stand on one leg (maximum 120 seconds).	Baseline, 3 months, 9 months
Secondary	Change from baseline functional balance at 3 months and at 9 months, respectively.	Step test, number of steps during 30 seconds.	Baseline, 3 months, 9 months
Secondary	Change from baseline anxiety and depression at 3 months and at 9 months, respectively.	Hospital anxiety and depression scale (HAD): range 0-42, higher score indicates more symptoms.	Baseline, 3 months, 9 months
Secondary	Change from baseline health related quality of life at 3 months and at 9 months, respectively.	Short Form Health Survey (SF-36): scores transformed to 0 to 100, higher scores indicates better quality of life.	Baseline, 3 months, 9 months
Secondary	Change from baseline self-efficacy at 3 months and at 9 months, respectively.	Swedish Exercise Self Efficacy Scale (ESES-S): Range 10-40, higher score indicates more self efficacy.	Baseline, 3 months, 9 months
Secondary	Change from baseline sleep quality at 3 months and at 9 months, respectively.	One question (no. 3) regarding sleep from Montgomery-Åsberg Depression Rating Scale (MADRS).	Baseline, 3 months, 9 months
Secondary	Change from baseline objective physical activity at 1.5 months (mid-training), at 3 months and at 9 months, respectively.	Physical activity measured by an activity monitor, the Actigraph. Number of steps per day and number of activity counts per day will be measured.	Baseline, 1.5 months, 3 months, 9 months
Secondary	Change from baseline self-reported physical activity at 1.5 months (mid-training), at 3 months and at 9 months, respectively.	Two indicator questions on physical activity from the Swedish National Board of Health and Welfare.	Baseline, 1.5 months, 3 months, 9 months
Secondary	Change from baseline metabolic health at 3 months and at 9 months, respectively.	Oral glucose tolerance test (OGTT):blood glucose in mmol/l,	Baseline, 3 months, 9 months
Secondary	Change from baseline lipid profile at 3 months and at 9 months, respectively.	Lipid profile, measured by total cholesterol as well as separately as LDL- cholesterol and HDL-cholesterol. Unit of measure is mmol/l.	Baseline, 3 months, 9 months
Secondary	Change from baseline inflammation markers at 3 months and at 9 months, respectively.	C-reactive protein (CRP) in blood sample, units of measure is mg/l.	Baseline, 3 months, 9 months
Secondary	Change from baseline inflammation markers at 3 months and at 9 months, respectively.	Interleukins in blood sample, units of measure is pg/ml.	Baseline, 3 months, 9 months
Secondary	Change from baseline neurotrophic factors at 3 months and at 9 months, respectively.	Insulin-like growth factor 1 (IGF-1), units of measure is pg/ml.	Baseline, 3 months, 9 months
Secondary	Change from baseline neurotrophic factors at 3 months and at 9 months, respectively.	Brain-derived neurotrophic factor (BDNF), units of measure is pg/ml.	Baseline, 3 months, 9 months
Secondary	Change from baseline blood pressure at 1.5 months (mid-training), at 3 months and at 9 months, respectively.	Blood pressure at rest, measured as systolic ans diastolic pressure in mmHg.	Baseline, 1.5 months, 3 months, 9 months
Secondary	Change from baseline resting heart rate at 1.5 months (mid-training), at 3 months and at 9 months, respectively.	Resting heart rate, measured as beats per minute.	Baseline, 1.5 months, 3 months, 9 months
Secondary	Change from baseline autonomic function at 1.5 months (mid-training), at 3 months and at 9 months, respectively.	Heart rate variability (HRV), measured in the time domain (e.g. RMSSD) and frequency domain (LF:HF).	Baseline, 1.5 months, 3 months, 9 months
Secondary	Applicability of the interventions	Attendance: number of sessions attended.	Through the whole 3-month intervention period
Secondary	Applicability of the interventions	Absolute work-load during training in Watt.	Through the whole 3-month intervention period
Secondary	Applicability of the interventions	Relative training intensity, as percentage of MAP (Maximum Aerobic Power output).	Through the whole 3-month intervention period
Secondary	Applicability of the interventions	Relative training intensity, as percentage of MHR (maximum heart rate).	Through the whole 3-month intervention period
Secondary	Applicability of the interventions	Perceived exertion during training, measured with the Borg Rating of perceived exertion scale (RPE)	Through the whole 3-month intervention period
Secondary	Applicability of the interventions	Adverse events, discomfort or chest pain during training measured with the Borg Category ratio scale (CR-10).	Through the whole 3-month intervention period
Secondary	Applicability of the interventions	Affective state during training session using Feeling Scale, range -5 to 5, higher score indicates better feeling.	Through the whole 3-month intervention period
Secondary	Experiences of exercising and its effects	Focus group interviews.	3 months, 9 months.